Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1

2-Hydroxypropyl-beta-cyclodextrin (HPβCD) has gained recent attention as a potential therapeutic intervention in the treatment of the rare autosomal-recessive, neurodegenerative lysosomal storage disorder Niemann-Pick Disease Type C1 (NPC1). Notably, HPβCD formulations are not comprised of a single molecular species, but instead are complex mixtures of species with differing degrees of hydroxypropylation of the cyclodextrin ring. The degree of substitution is a critical aspect of the complex mixture as it influences binding to other molecules and thus could potentially modulate biological effects. VTS-270 (Kleptose HPB) and Trappsol® Cyclo™ are HPβCD products under investigation as novel treatments for NPC1. The purpose of the present work is to compare these two different products; analyses were based on ion distribution and abundance profiles using mass spectrometry methodology as a means for assessing key molecular distinctions between products. The method incorporated electrospray ionization and analysis with a linear low-field ion mobility quadrupole time-of-flight instrument. We observed that the number of hydroxypropyl groups (the degrees of substitution) are substantially different between the two products and greater in Trappsol Cyclo than in VTS-270. The principal ions of both samples are ammonium adducts. Isotope clusters for each of the major ions show doubly charged homodimers of the ammonium adducts. In addition, both products show doubly charged homodimers from adduction of both a proton and ammonium. Doubly charged heterodimers are also present, but are more intense in Trappsol Cyclo than in VTS-270. Based on the analytical differences observed between VTS-270 and Trappsol Cyclo with respect to the degree of substitution, the composition and fingerprint of the complex mixture, and the impurity profiles, these products cannot be considered to be the same; the potential biological and clinical implications of these differences are not presently known.

[1]  L. Fenart,et al.  Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases , 2016, Molecules.

[2]  J. Poveda,et al.  Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients , 2016, Journal of the Neurological Sciences.

[3]  S. Chaieb,et al.  Cholesterol Depletion from a Ceramide/Cholesterol Mixed Monolayer: A Brewster Angle Microscope Study , 2016, Scientific Reports.

[4]  S. Walkley,et al.  Efficacy and ototoxicity of different cyclodextrins in Niemann–Pick C disease , 2016, Annals of clinical and translational neurology.

[5]  Paul Gissen,et al.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease , 2016, Therapeutic advances in neurological disorders.

[6]  C. Vite,et al.  Phase 1/2 evaluation of intrathecal 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease type C1 , 2016 .

[7]  Jody C. May,et al.  Broadscale resolving power performance of a high precision uniform field ion mobility-mass spectrometer. , 2015, The Analyst.

[8]  C. Vite,et al.  Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease , 2015, Science Translational Medicine.

[9]  M. Vanier Complex lipid trafficking in Niemann-Pick disease type C , 2015, Journal of Inherited Metabolic Disease.

[10]  F. Sedel,et al.  Niemann-Pick disease type C symptomatology: an expert-based clinical description , 2013, Orphanet Journal of Rare Diseases.

[11]  F. Cowan,et al.  604 Large Focal Cerebral Haematomas: Neonatal Presentation and Outcome , 2010 .

[12]  J. Repa,et al.  Weekly Cyclodextrin Administration Normalizes Cholesterol Metabolism in Nearly Every Organ of the Niemann-Pick Type C1 Mouse and Markedly Prolongs Life , 2010, Pediatric Research.

[13]  D. Ory,et al.  Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression , 2009, PloS one.

[14]  M. Másson,et al.  Cyclodextrins in drug delivery , 2005, Expert opinion on drug delivery.

[15]  Edward A. Mason,et al.  Transport Properties of Ions in Gases: MASON:TRANSPORT PROPERTIES O-BK , 2005 .

[16]  H. Schneider,et al.  NMR Studies of Cyclodextrins and Cyclodextrin Complexes. , 1998, Chemical reviews.

[17]  E. W. McDaniel,et al.  Transport Properties of Ions in Gases , 1988 .

[18]  L. Pannell,et al.  Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs , 1986 .